Daniel Grill | Tetra Images | Getty Images
Altimmune announced that its experimental drug not only helped patients lose weight but also minimized the loss of muscle mass in a mid-stage trial. This could potentially differentiate it in a crowded market, competing directly with Novo Nordisk and Eli Lilly in the weight loss drug space.
These results are an early indication that Altimmune may be able to address a major concern surrounding weight loss treatments, which have seen significant demand and investor interest in the past year.
Obesity drugs have raised concerns about shrinking critical muscle mass, increasing the risk of injuries and decreasing strength. However, in Altimmune’s late-stage trial, more than 74% of the weight lost by patients came from fat tissue, alleviating these concerns.
Altimmune is among several smaller biotech companies vying for a position in the weight loss drug market, with the potential to be acquired by larger drugmakers to bring their treatments to market.
For more details, you can visit the original article here.
2024-03-27 13:30:36